peer reviewedA drug‐induced sarcoidosis‐like reaction is a systemic granulomatous reaction indistinguishable from sarcoidosis and occurring in temporal relationship with a drug initiation. In this article, we report a patient who developed lung and liver granulomatous lesions following tocilizumab initiation for a giant cell arteritis. Infectious, toxic, neoplastic and inflammatory differential diagnoses were ruled out and lesions regressed after treatment cessation, leading to the diagnosis of tocilizumab induced sarcoidosis‐like reaction. We review the six cases reported so far and emphasize the value of a prompt diagnosis. Finally, we discuss the potential pathophysiological mechanisms underlying this rare reaction, which could help to b...
A 66-year-old woman rheumatoid arthritis was treated with methotrexate and tocilizumab. Chest radiog...
Introduction: Infliximab is a chimeric anti-tumor necrosis alpha (TNF-α) monoclonal antibody that in...
Nivolumab, an anti-PD-1 antibody, inhibits binding between PD-1 and PD-1 ligand and activates antige...
peer reviewedA drug‐induced sarcoidosis‐like reaction is a systemic granulomatous reaction indisting...
AbstractSarcoidosis is a multisystem granulomatous inflammatory disease of unknown etiology. There i...
Sarcoidosis is a systemic chronic granulomatous disease of unknown etiology. It predominantly involv...
Sarcoid like reaction is a well-known entity that occurs as a consequence to several malignancies or...
Abstract Immune checkpoint inhibitors (ICIs) have become the standard of care for the treatment of n...
Objectives: to report 2 cases of sarcoidosis developed during treatment with anti-TNFalfa antagonist...
PURPOSE OF REVIEW: Sarcoidosis is a complex granulomatous disease of unknown cause. Several drug cat...
International audienceAnti-TNF-alpha agents have been tried in cases of refractory sarcoidosis, givi...
We report a case of anti-protein death 1-induced sarcoid-like reaction in a 63-year-old Caucasian ma...
We aimed to review the clinical and biological presentation of granulomatosis associated with immune...
International audienceOBJECTIVE: TNF blockers have been recently evaluated for treating refractory s...
Adalimumab is a full human monoclonal antibody that inhibits tumor necrosis factor-alpha (TNF-${\alp...
A 66-year-old woman rheumatoid arthritis was treated with methotrexate and tocilizumab. Chest radiog...
Introduction: Infliximab is a chimeric anti-tumor necrosis alpha (TNF-α) monoclonal antibody that in...
Nivolumab, an anti-PD-1 antibody, inhibits binding between PD-1 and PD-1 ligand and activates antige...
peer reviewedA drug‐induced sarcoidosis‐like reaction is a systemic granulomatous reaction indisting...
AbstractSarcoidosis is a multisystem granulomatous inflammatory disease of unknown etiology. There i...
Sarcoidosis is a systemic chronic granulomatous disease of unknown etiology. It predominantly involv...
Sarcoid like reaction is a well-known entity that occurs as a consequence to several malignancies or...
Abstract Immune checkpoint inhibitors (ICIs) have become the standard of care for the treatment of n...
Objectives: to report 2 cases of sarcoidosis developed during treatment with anti-TNFalfa antagonist...
PURPOSE OF REVIEW: Sarcoidosis is a complex granulomatous disease of unknown cause. Several drug cat...
International audienceAnti-TNF-alpha agents have been tried in cases of refractory sarcoidosis, givi...
We report a case of anti-protein death 1-induced sarcoid-like reaction in a 63-year-old Caucasian ma...
We aimed to review the clinical and biological presentation of granulomatosis associated with immune...
International audienceOBJECTIVE: TNF blockers have been recently evaluated for treating refractory s...
Adalimumab is a full human monoclonal antibody that inhibits tumor necrosis factor-alpha (TNF-${\alp...
A 66-year-old woman rheumatoid arthritis was treated with methotrexate and tocilizumab. Chest radiog...
Introduction: Infliximab is a chimeric anti-tumor necrosis alpha (TNF-α) monoclonal antibody that in...
Nivolumab, an anti-PD-1 antibody, inhibits binding between PD-1 and PD-1 ligand and activates antige...